Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.

Phase 3CompletedNCT00141362

Pfizer325 enrolled

Overview

Evaluate long-term safety and efficacy of pregabalin in patients with chronic neuropathic pain.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

325

Conditions

Pain

Interventions

PregabalinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must have met the inclusion criteria for the preceding double-blind BID study in diabetic neuropathy or postherpetic neuralgia. * Must have received study medication under double-blind conditions. Exclusion Criteria: * Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.

Outcomes

Primary Outcomes

Safety and efficacy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.